HBP — Helix Biopharma Income Statement
0.000.00%
Last trade - 00:00
- CA$61.77m
- CA$61.06m
2019 July 31st | 2020 July 31st | 2021 July 31st | 2022 July 31st | 2023 July 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7.49 | 8.62 | 9.13 | 6.04 | 6.33 |
Operating Profit | -7.49 | -8.62 | -9.13 | -6.04 | -6.33 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7.53 | -8.56 | -9.57 | -6.56 | -6.29 |
Net Income After Taxes | -7.53 | -8.56 | -9.57 | -6.56 | -6.29 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -7.53 | -8.98 | -8.04 | -6.56 | -6.29 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.53 | -8.98 | -8.04 | -6.56 | -6.29 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.353 | -0.328 | -0.347 | -0.22 | -0.163 |